This page has only limited features, please log in for full access.
Background Bariatric surgery results in rapid weight loss and resolution of comorbidities such as type 2 diabetes mellitus (T2DM). We aimed to determine whether the type of surgical procedure—vertical sleeve gastrectomy (VSG) versus Roux-en-Y gastric bypass (RYGB)—was associated with sustained remission from T2DM, and to identify other independent predictors of sustained remission. Methods Using the IBM MarketScan database of privately insured patients in the United States, we performed a retrospective cohort study on individuals aged 18-65 y with T2DM on hypoglycemic medication, who underwent either VSG or RYGB from 2010 to 2016. Remission was defined as no refill of antidiabetic medication 180 d after a patient's medication was expected to run out and recurrence as medication refill after at least 180 d of remission. Results Of 5119 patients in our cohort, 4127 (81%) experienced remission of T2DM, and 816 (19.8%) of the 4127 patients experienced recurrence. Patients who underwent RYGB had a 24% (HR = 1.24, 95% CI: 1.16, 1.32) increased probability of achieving remission compared with VSG. RYGB had a 36% (HR = 0.64, 95% CI: 0.55, 0.74) decreased risk of recurrence compared with VSG. A higher number of diabetic medications at the time of surgery and a higher Charlson index score were associated with decreased probability of remission and an increased risk of recurrence of T2DM. Conclusions While both procedures are initially effective, RYGB may be better than VSG at providing lasting remission of T2DM.
Richard D. Nudotor; Gregory Prokopowicz; Enoch J. Abbey; Aldo Gonzalez; Joseph K. Canner; Kimberley E. Steele. Comparative Effectiveness of Roux-en Y Gastric Bypass Versus Vertical Sleeve Gastrectomy for Sustained Remission of Type 2 Diabetes Mellitus. Journal of Surgical Research 2021, 261, 407 -416.
AMA StyleRichard D. Nudotor, Gregory Prokopowicz, Enoch J. Abbey, Aldo Gonzalez, Joseph K. Canner, Kimberley E. Steele. Comparative Effectiveness of Roux-en Y Gastric Bypass Versus Vertical Sleeve Gastrectomy for Sustained Remission of Type 2 Diabetes Mellitus. Journal of Surgical Research. 2021; 261 ():407-416.
Chicago/Turabian StyleRichard D. Nudotor; Gregory Prokopowicz; Enoch J. Abbey; Aldo Gonzalez; Joseph K. Canner; Kimberley E. Steele. 2021. "Comparative Effectiveness of Roux-en Y Gastric Bypass Versus Vertical Sleeve Gastrectomy for Sustained Remission of Type 2 Diabetes Mellitus." Journal of Surgical Research 261, no. : 407-416.
To investigate the association of the two most common bariatric surgical procedures, vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB), with sustained remission from chronic migraine. Using IBM MarketScan® research database to examine inpatient and pharmacy claims from 2010 through 2017. A cohort of bariatric patients with chronic migraine was created using inclusion and exclusion criteria. Remission was defined as no refill of first-line migraine medication for 180 days after a patients’ medication was expected to run out, and recurrence as medication refill after at least 180 days of remission. Of 1680 patients in our cohort, 931 (55.4%) experienced remission of migraine. Of these, 462 (49.6%) had undergone VSG, while 469 (50.4%) had undergone RYGB. Patients who underwent RYGB had an 11% (RR = 1.11, 95% CI: 1.05, 1.17) increase in likelihood of remission of migraine and a 20% (RR = 0.80, 95% CI: 0.63, 1.04) decrease in likelihood of recurrence of migraine compared to patients who underwent VSG. Older age group, higher number of medications at time of surgery, and female sex were associated with a decreased likelihood of remission. Type of bariatric procedure, age, number of medications at surgery, and sex were the most important predictors of migraine remission after surgery.
Richard Nudotor; Hasiya Yusuf; Owulatobi Lasisi; Emmanuella Salia; Banda Khalifa; Enoch Abbey; Modupe Oduwole; Samuel Ayeh; Obeng Appiafo; Joseph Canner; Ann Scheimann; Kimberley E. Steele. A Retrospective Analysis of the Impact of Bariatric Surgery on the Management of Chronic Migraine. Obesity Surgery 2021, 31, 2040 -2049.
AMA StyleRichard Nudotor, Hasiya Yusuf, Owulatobi Lasisi, Emmanuella Salia, Banda Khalifa, Enoch Abbey, Modupe Oduwole, Samuel Ayeh, Obeng Appiafo, Joseph Canner, Ann Scheimann, Kimberley E. Steele. A Retrospective Analysis of the Impact of Bariatric Surgery on the Management of Chronic Migraine. Obesity Surgery. 2021; 31 (5):2040-2049.
Chicago/Turabian StyleRichard Nudotor; Hasiya Yusuf; Owulatobi Lasisi; Emmanuella Salia; Banda Khalifa; Enoch Abbey; Modupe Oduwole; Samuel Ayeh; Obeng Appiafo; Joseph Canner; Ann Scheimann; Kimberley E. Steele. 2021. "A Retrospective Analysis of the Impact of Bariatric Surgery on the Management of Chronic Migraine." Obesity Surgery 31, no. 5: 2040-2049.
Background Bariatric surgery results in rapid weight loss and resolution of many comorbidities including hypertension. Objectives To investigate the association of the two most common bariatric surgical procedures, vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB), with sustained remission from hypertension, and evaluate other independent predictors of sustained remission. Setting Privately insured patients with hypertension in the United States undergoing bariatric surgery. Methods A cohort of hypertensive bariatric patients was created using detailed inclusion and exclusion criteria. Remission was defined as no refill of antihypertensive medication for 30 days after a patients' medication was expected to run out, and recurrence as medication refill after at least 90 days of remission. Results Of 7006 patients in our cohort, 5,874 experienced remission of their hypertension (83.8%). 745 of the 5874 (12.7%) patients later experienced recurrence. The adjusted hazard ratio of remission for VSG compared to RYGB was 1.06 [95% CI; 1.0, 1.11.] The adjusted hazard ratio of recurrence for VSG compared to RYGB was 0.84 [95% CI; 0.71, 0.97]. A higher number of medications at the time of surgery was associated with a decreased likelihood of remission and an increased risk of recurrence of hypertension. Conclusion There was no difference in the likelihood of remission of hypertension between VSG and RYGB. The number of medications at the time of surgery was the most important predictor of remission and recurrence of hypertension after surgery.
R.D. Nudotor; J.K. Canner; E.R. Haut; G.P. Prokopowicz; K.E. Steele. Comparing remission and recurrence of hypertension after bariatric surgery: vertical sleeve gastrectomy versus Roux-en-Y gastric bypass. Surgery for Obesity and Related Diseases 2020, 17, 308 -318.
AMA StyleR.D. Nudotor, J.K. Canner, E.R. Haut, G.P. Prokopowicz, K.E. Steele. Comparing remission and recurrence of hypertension after bariatric surgery: vertical sleeve gastrectomy versus Roux-en-Y gastric bypass. Surgery for Obesity and Related Diseases. 2020; 17 (2):308-318.
Chicago/Turabian StyleR.D. Nudotor; J.K. Canner; E.R. Haut; G.P. Prokopowicz; K.E. Steele. 2020. "Comparing remission and recurrence of hypertension after bariatric surgery: vertical sleeve gastrectomy versus Roux-en-Y gastric bypass." Surgery for Obesity and Related Diseases 17, no. 2: 308-318.
BackgroundCOVID-19 has heterogeneous manifestations, though one of the most common symptoms is a sudden loss of smell (anosmia or hyposmia). We investigated whether olfactory loss is a reliable predictor of COVID-19.MethodsThis preregistered, cross-sectional study used a crowdsourced questionnaire in 23 languages to assess symptoms in individuals self-reporting recent respiratory illness. We quantified changes in chemosensory abilities during the course of the respiratory illness using 0-100 visual analog scales (VAS) for participants reporting a positive (C19+; n=4148) or negative (C19-; n=546) COVID-19 laboratory test outcome. Logistic regression models identified singular and cumulative predictors of COVID-19 status and post-COVID-19 olfactory recovery.ResultsBoth C19+ and C19-groups exhibited smell loss, but it was significantly larger in C19+ participants (mean±SD, C19+: -82.5±27.2 points; C19-: -59.8±37.7). Smell loss during illness was the best predictor of COVID-19 in both single and cumulative feature models (ROC AUC=0.72), with additional features providing negligible model improvement. VAS ratings of smell loss were more predictive than binary chemosensory yes/no-questions or other cardinal symptoms, such as fever or cough. Olfactory recovery within 40 days was reported for ∼50% of participants and was best predicted by time since illness onset.ConclusionsAs smell loss is the best predictor of COVID-19, we developed the ODoR-19 tool, a 0-10 scale to screen for recent olfactory loss. Numeric ratings ≤2 indicate high odds of symptomatic COVID-19 (4
Richard C. Gerkin; Kathrin Ohla; Maria Geraldine Veldhuizen; Paule V. Joseph; Christine E. Kelly; Alyssa J. Bakke; Kimberley E. Steele; Michael C. Farruggia; Robert Pellegrino; Marta Y. Pepino; Cédric Bouysset; Graciela M. Soler; Veronica Pereda-Loth; Michele Dibattista; Keiland W. Cooper; Ilja Croijmans; Antonella Di Pizio; M. Hakan Ozdener; Alexander W. Fjaeldstad; Cailu Lin; Mari A. Sandell; Preet B. Singh; V. Evelyn Brindha; Shannon B. Olsson; Luis R. Saraiva; Gaurav Ahuja; Mohammed K. Alwashahi; Surabhi Bhutani; Anna D’Errico; Marco A. Fornazieri; Jérôme Golebiowski; Liang-Dar Hwang; Elif E. Ozturk; Eugeni Roura; Sara Spinelli; Katherine L. Whitcroft; Farhoud Faraji; Florian Ph.S Fischmeister; Thomas Heinbockel; Julien W. Hsieh; Caroline Huart; Iordanis Konstantinidis; Anna Menini; Gabriella Morini; Jonas K. Olofsson; Carl M. Philpott; Denis Pierron; Vonnie D. C. Shields; Vera V. Voznessenskaya; Javier Albayay; Aytug Altundag; Moustafa Bensafi; María Adelaida Bock; Orietta Calcinoni; William Fredborg; Christophe Laudamiel; Juyun Lim; Johan N. Lundström; Alberto Macchi; Pablo Meyer; Shima T. Moein; Enrique Santamaría; Debarka Sengupta; Paloma Rohlfs Dominguez; Hüseyin Yanik; Thomas Hummel; John E. Hayes; Danielle R. Reed; Masha Y. Niv; Steven D. Munger; Valentina Parma; GCCR Group Author; Non-byline authors (to be listed as collaborators in PubMed under the GCCR Group Author). The best COVID-19 predictor is recent smell loss: a cross-sectional study. 2020, 1 .
AMA StyleRichard C. Gerkin, Kathrin Ohla, Maria Geraldine Veldhuizen, Paule V. Joseph, Christine E. Kelly, Alyssa J. Bakke, Kimberley E. Steele, Michael C. Farruggia, Robert Pellegrino, Marta Y. Pepino, Cédric Bouysset, Graciela M. Soler, Veronica Pereda-Loth, Michele Dibattista, Keiland W. Cooper, Ilja Croijmans, Antonella Di Pizio, M. Hakan Ozdener, Alexander W. Fjaeldstad, Cailu Lin, Mari A. Sandell, Preet B. Singh, V. Evelyn Brindha, Shannon B. Olsson, Luis R. Saraiva, Gaurav Ahuja, Mohammed K. Alwashahi, Surabhi Bhutani, Anna D’Errico, Marco A. Fornazieri, Jérôme Golebiowski, Liang-Dar Hwang, Elif E. Ozturk, Eugeni Roura, Sara Spinelli, Katherine L. Whitcroft, Farhoud Faraji, Florian Ph.S Fischmeister, Thomas Heinbockel, Julien W. Hsieh, Caroline Huart, Iordanis Konstantinidis, Anna Menini, Gabriella Morini, Jonas K. Olofsson, Carl M. Philpott, Denis Pierron, Vonnie D. C. Shields, Vera V. Voznessenskaya, Javier Albayay, Aytug Altundag, Moustafa Bensafi, María Adelaida Bock, Orietta Calcinoni, William Fredborg, Christophe Laudamiel, Juyun Lim, Johan N. Lundström, Alberto Macchi, Pablo Meyer, Shima T. Moein, Enrique Santamaría, Debarka Sengupta, Paloma Rohlfs Dominguez, Hüseyin Yanik, Thomas Hummel, John E. Hayes, Danielle R. Reed, Masha Y. Niv, Steven D. Munger, Valentina Parma, GCCR Group Author, Non-byline authors (to be listed as collaborators in PubMed under the GCCR Group Author). The best COVID-19 predictor is recent smell loss: a cross-sectional study. . 2020; ():1.
Chicago/Turabian StyleRichard C. Gerkin; Kathrin Ohla; Maria Geraldine Veldhuizen; Paule V. Joseph; Christine E. Kelly; Alyssa J. Bakke; Kimberley E. Steele; Michael C. Farruggia; Robert Pellegrino; Marta Y. Pepino; Cédric Bouysset; Graciela M. Soler; Veronica Pereda-Loth; Michele Dibattista; Keiland W. Cooper; Ilja Croijmans; Antonella Di Pizio; M. Hakan Ozdener; Alexander W. Fjaeldstad; Cailu Lin; Mari A. Sandell; Preet B. Singh; V. Evelyn Brindha; Shannon B. Olsson; Luis R. Saraiva; Gaurav Ahuja; Mohammed K. Alwashahi; Surabhi Bhutani; Anna D’Errico; Marco A. Fornazieri; Jérôme Golebiowski; Liang-Dar Hwang; Elif E. Ozturk; Eugeni Roura; Sara Spinelli; Katherine L. Whitcroft; Farhoud Faraji; Florian Ph.S Fischmeister; Thomas Heinbockel; Julien W. Hsieh; Caroline Huart; Iordanis Konstantinidis; Anna Menini; Gabriella Morini; Jonas K. Olofsson; Carl M. Philpott; Denis Pierron; Vonnie D. C. Shields; Vera V. Voznessenskaya; Javier Albayay; Aytug Altundag; Moustafa Bensafi; María Adelaida Bock; Orietta Calcinoni; William Fredborg; Christophe Laudamiel; Juyun Lim; Johan N. Lundström; Alberto Macchi; Pablo Meyer; Shima T. Moein; Enrique Santamaría; Debarka Sengupta; Paloma Rohlfs Dominguez; Hüseyin Yanik; Thomas Hummel; John E. Hayes; Danielle R. Reed; Masha Y. Niv; Steven D. Munger; Valentina Parma; GCCR Group Author; Non-byline authors (to be listed as collaborators in PubMed under the GCCR Group Author). 2020. "The best COVID-19 predictor is recent smell loss: a cross-sectional study." , no. : 1.
Bariatric surgeries are the most effective treatments for successful and sustained weight loss but individuals vary in treatment response. Understanding the neurobiological and behavioral mechanisms accounting for this variation could lead to the development of personalized therapeutic approaches and improve treatment outcomes. The primary objectives were to investigate changes in taste preferences and taste-induced brain responses after Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) and to identify potential taste-related predictors of weight loss. Women, ages 18 to 55, with a body mass index ≥ 35 kg/m2 and approved for bariatric surgery at the Johns Hopkins Center for Bariatric Surgery were recruited for participation. Demographics, anthropometrics, liking ratings, and neural responses to varying concentrations of sucrose+fat mixtures were assessed pre- and post-surgery via visual analogue scales and functional magnetic resonance imaging. Bariatric surgery produced decreases in liking for sucrose-sweetened mixtures. Greater preference for sucrose-sweetened mixtures prior to surgery was associated with greater weight loss in RYGB but not VSG. In the RYGB group only, individuals who showed lower taste-induced activation in the ventral tegmental area (VTA) prior to surgery and greater changes in taste-induced VTA activation two weeks following surgery experienced better weight loss. The anatomical and/or metabolic changes associated with RYGB may more effectively "reset" the neural processing of reward stimuli, thereby rescuing the blunted activation in the mesolimbic pathway found in patients with obesity. Further, these findings suggest that RYGB may be particularly effective in patients with a preference for sweet foods. Not Applicable. K23DK100559 and The Dalio Philanthropies. K23DK100559 and The Dalio Philanthropies.
Kimberly R. Smith; Afroditi Papantoni; Maria G. Veldhuizen; Vidyulata Kamath; Civonnia Harris; Timothy H. Moran; Susan Carnell; Kimberley E. Steele. Taste-related reward is associated with weight loss following bariatric surgery. Journal of Clinical Investigation 2020, 1 .
AMA StyleKimberly R. Smith, Afroditi Papantoni, Maria G. Veldhuizen, Vidyulata Kamath, Civonnia Harris, Timothy H. Moran, Susan Carnell, Kimberley E. Steele. Taste-related reward is associated with weight loss following bariatric surgery. Journal of Clinical Investigation. 2020; ():1.
Chicago/Turabian StyleKimberly R. Smith; Afroditi Papantoni; Maria G. Veldhuizen; Vidyulata Kamath; Civonnia Harris; Timothy H. Moran; Susan Carnell; Kimberley E. Steele. 2020. "Taste-related reward is associated with weight loss following bariatric surgery." Journal of Clinical Investigation , no. : 1.
Background Bariatric embolization is a new endovascular procedure to treat patients with obesity. However, the safety and efficacy of bariatric embolization are unknown. Purpose To evaluate the safety and efficacy of bariatric embolization in severely obese adults at up to 12 months after the procedure. Materials and Methods For this prospective study (NCT0216512 on ClinicalTrials.gov ), 20 participants (16 women) aged 27-68 years (mean ± standard deviation, 44 years ± 11) with mean body mass index of 45 ± 4.1 were enrolled at two institutions from June 2014 to February 2018. Transarterial embolization of the gastric fundus was performed using 300- to 500-µm embolic microspheres. Primary end points were 30-day adverse events and weight loss at up to 12 months. Secondary end points at up to 12 months included technical feasibility, health-related quality of life (Short Form-36 Health Survey ([SF-36]), impact of weight on quality of life (IWQOL-Lite), and hunger or appetite using a visual assessment scale. Analysis of outcomes was performed by using one-sample t tests and other exploratory statistics. Results Bariatric embolization was performed successfully for all participants with no major adverse events. Eight participants had a total of 11 minor adverse events. Mean excess weight loss was 8.2% (95% confidence interval [CI]: 6.3%, 10%; P < .001) at 1 month, 11.5% (95% CI: 8.7%, 14%; P < .001) at 3 months, 12.8% (95% CI: 8.3%, 17%; P < .001) at 6 months, and 11.5% (95% CI: 6.8%, 16%; P < .001) at 12 months. From baseline to 12 months, mean SF-36 scores increased (mental component summary, from 46 ± 11 to 50 ± 10, P = .44; physical component summary, from 46 ± 8.0 to 50 ± 9.3, P = .15) and mean IWQOL-Lite scores increased from 57 ± 18 to 77 ± 18 (P < .001). Hunger or appetite decreased for 4 weeks after embolization and increased thereafter, without reaching pre-embolization levels. Conclusion Bariatric embolization is well tolerated in severely obese adults, inducing appetite suppression and weight loss for up to 12 months. Published under a CC BY-NC-ND 4.0 license. Online supplemental material is available for this article.
Clifford R. Weiss; Godwin O. Abiola; Aaron M. Fischman; Lawrence J. Cheskin; Jay Vairavamurthy; Brian P. Holly; Olaguoke Akinwande; Franklin Nwoke; Kalyan Paudel; Stephen Belmustakov; Kelvin Hong; Rahul S. Patel; Eun J. Shin; Kimberley E. Steele; Timothy H. Moran; Richard E. Thompson; Taylor Dunklin; Harvey Ziessman; Dara L. Kraitchman; Aravind Arepally. Bariatric Embolization of Arteries for the Treatment of Obesity (BEAT Obesity) Trial: Results at 1 Year. Radiology 2019, 291, 792 -800.
AMA StyleClifford R. Weiss, Godwin O. Abiola, Aaron M. Fischman, Lawrence J. Cheskin, Jay Vairavamurthy, Brian P. Holly, Olaguoke Akinwande, Franklin Nwoke, Kalyan Paudel, Stephen Belmustakov, Kelvin Hong, Rahul S. Patel, Eun J. Shin, Kimberley E. Steele, Timothy H. Moran, Richard E. Thompson, Taylor Dunklin, Harvey Ziessman, Dara L. Kraitchman, Aravind Arepally. Bariatric Embolization of Arteries for the Treatment of Obesity (BEAT Obesity) Trial: Results at 1 Year. Radiology. 2019; 291 (3):792-800.
Chicago/Turabian StyleClifford R. Weiss; Godwin O. Abiola; Aaron M. Fischman; Lawrence J. Cheskin; Jay Vairavamurthy; Brian P. Holly; Olaguoke Akinwande; Franklin Nwoke; Kalyan Paudel; Stephen Belmustakov; Kelvin Hong; Rahul S. Patel; Eun J. Shin; Kimberley E. Steele; Timothy H. Moran; Richard E. Thompson; Taylor Dunklin; Harvey Ziessman; Dara L. Kraitchman; Aravind Arepally. 2019. "Bariatric Embolization of Arteries for the Treatment of Obesity (BEAT Obesity) Trial: Results at 1 Year." Radiology 291, no. 3: 792-800.